Journal of Multidisciplinary Healthcare

Global Advances in Pharmacogenomics: From Discovery to Clinical Implementation and Improved Patient Outcomes

Journal of Multidisciplinary Healthcare is pleased to welcome you to submit your research to the Article Collection "Global Advances in Pharmacogenomics: From Discovery to Clinical Implementation and Improved Patient Outcomes".

Pharmacogenomics has emerged as the primary driver of treatment individualization, moving beyond a "one-size-fits-all" approach to a model where drug selection and dosages are tailored to an individual’s genetic profile. While the field has seen rapid growth in identifying genetic variants that influence drug-metabolizing enzymes and drug targets, the focus is now shifting toward the practical integration of these findings into routine healthcare. This Article Collection explores the full spectrum of PGx, from foundational variability studies to the latest in diagnostic methodologies.

The importance of this topic lies in its potential to bridge the gap between genomic discovery and clinical utility. By optimizing therapeutic efficacy and minimizing adverse drug reactions (ADRs), pharmacogenomics serves as a critical tool for improving patient safety and healthcare cost-effectiveness globally. Understanding the genetic diversity across different populations is essential to ensure that the benefits of personalized medication management are equitable and scientifically sound for all patients.

Specific Topics of Interest include:

• Clinical Utility: Real-world evidence of PGx-guided therapy in specialties such as oncology, cardiology, and psychiatry.
• Testing Methodologies: Development and validation of innovative, scalable, or cost-effective pharmacogenetic testing platforms.
• Genetic Variability: Studies on the prevalence and impact of polymorphisms in drug-metabolizing enzymes and transporters across diverse global populations.
• Implementation Science: Strategies for integrating PGx into clinical workflows, including electronic health record (EHR) integration and clinical decision support.
• Policy and Ethics: Ethical, legal, and social implications (ELSI), along with policy recommendations for national healthcare systems
• Medication Safety & ADR Management: The role of multidisciplinary teams in monitoring and preventing adverse drug reactions as a foundation for personalized therapy.

This Article Collection seeks to highlight the essential multidisciplinary collaboration between clinical pharmacists, physicians, molecular biologists, and bioinformaticians required to move pharmacogenomics from theory to practice. We invite submissions that demonstrate how integrated healthcare teams utilize genetic data to optimize therapeutic outcomes and patient safety across diverse clinical settings. The Collection particularly welcomes Original Research, Reviews, Clinical Trial Reports, Methodologies, Perspectives, and Expert Opinions that provide robust evidence for implementation. Systematic Reviews that synthesize current knowledge of genetic variability and its clinical implications are also highly encouraged.

Meet the Guest Advisor

Dr. Mohamed Nagy is a clinical pharmacogenomics expert with extensive experience in research, teaching, and clinical practice. He is the Pharmacy Director at the Children's Cancer Hospital Egypt (CCHE) 57357, where he also founded and heads the Personalized Medication Management Unit. Dr. Nagy's research interests lie in pharmacogenomics, particularly in the application of genetic information to optimize drug therapy in pediatric oncology patients. Dr. Nagy serves on the board of the African Pharmacogenomics Network and is the chair of the global committee of the Pharmacogenomics Global Research Network.

The Guest Advisors declare no conflict of interest regarding this work.